YouTube · Q2 2026 · 2026-08-05
BDX · NYSE
Becton, Dickinson and Company
Medical Instruments & Supplies · United States
- Market cap (USD)
- US$50.71B
- Trailing P/E
- 43.30x
- Forward P/E
- 13.99x
- Quarterly revenue growth
- 5.4%
- Trailing net margin
- 4.2%
- Indicated dividend yield
- 2.3%
Snapshot 2026-10-06 · Latest financial period 2026-06-30 · Yahoo Finance. Quotes may be delayed; reporting periods can differ.
Next earnings: 2026-11-05 (provider estimate, not issuer-confirmed).
Company background
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
Company websiteQ3 FY2026
Go beyond the headline.
Comparable businesses
BDX peer comparison
Same business group first, then company size. Preferred market cap: 0.5–2x; extended range: one-third–3x. Outside that range, industry benchmarks are labeled separately and excluded from peer medians.
| Metric | BDXBecton, Dickinson and CompanySnapshot 2026-10-06Financial period: 2026-06-30 | MDLNMedline Inc.Snapshot 2026-10-06Financial period: 2026-06-27 | ALCAlcon Inc.Snapshot 2026-10-06Financial period: 2026-06-30 | Peer medianSimilar-size peers only |
|---|---|---|---|---|
| Market capMarket value, converted to USD | US$50.71B | US$49.42B | US$30.66B | US$40.04Bn=2 |
| Forward P/EProvider forward earnings estimate | 13.99x | 23.29x | 15.98x | 19.64xn=2 |
| EV / EBITDAEnterprise value / trailing EBITDA | 10.67x | 19.40x | 14.53x | 16.97xn=2 |
| Revenue growthLatest quarter vs prior-year quarter | 5.4% | 11.6% | 8.7% | 10.2%n=2 |
| Operating marginLatest reported quarter | 15.7% | 0.8% | 14.6% | 7.7%n=2 |
| Free cash flow yieldTrailing cash flow / market cap | 8.8% | 1.7% | 4.2% | 2.9%n=2 |
| Net debt / EBITDANet debt / trailing EBITDA | 2.63x | 3.95x | 1.60x | 2.77xn=2 |
| Debt / equityTotal debt / positive book equity | 0.69x | 0.66x | 0.25x | 0.45xn=2 |
| Trailing P/ETrailing twelve-month earnings | 43.30x | 91.83x | 48.05x | 69.94xn=2 |
| Price / bookPrice / positive book equity per share | 2.08x | 2.78x | 1.42x | 2.10xn=2 |
| EV / salesEnterprise value / trailing revenue | 2.90x | 1.63x | 3.22x | 2.42xn=2 |
| Earnings growthLatest quarter vs prior-year quarter | -31.4% | 262.0% | — | — |
| Gross marginTrailing twelve months | 46.9% | 25.1% | 57.2% | 41.2%n=2 |
| Net marginTrailing twelve months | 4.2% | 2.3% | 5.9% | 4.1%n=2 |
| Return on equityProvider trailing return; positive equity only | 6.6% | 4.9% | 2.9% | 3.9%n=2 |
| Free cash flow marginTrailing free cash flow / revenue | 19.9% | 2.8% | 11.7% | 7.3%n=2 |
| Dividend yieldIndicated annual dividend / price | 2.3% | — | 0.6% | — |
| Earnings payoutProvider trailing dividend payout | 72.5% | 0.0% | 26.6% | 13.3%n=2 |
| Current ratioCurrent assets / current liabilities | 0.86x | 4.33x | 2.09x | 3.21xn=2 |
| BetaProvider historical market sensitivity | 0.28 | — | 0.73 | — |
YouTube · Q2 2026 · 2026-08-05
YouTube · Q2 2026 · 2026-08-13
Comparison methodology & limitations
Reviewed operating groups override broad sector classifications. Other companies are matched only within a sufficiently specific provider industry. Business mix, geography and accounting standards can still differ. Market caps are converted to USD using exchange rates captured during the snapshot refresh. Financial ratios that would mix currencies are omitted. Snapshots must be at most 14 days old and no more than seven days apart for automatic selection.
Peer medians require at least two valid similar-size peers for each metric. Negative earnings, nonpositive equity, missing data and irrelevant bank ratios are not presented as attractive valuations. A higher or lower number is not automatically a better investment. Financial statement periods are not calendar-aligned across companies.
Reported performance
Financial trends
Periods are grouped by their ending calendar year or quarter, not identical fiscal calendars. Exact period-end dates appear in tooltips and reported figures. When reporting currencies differ and a recent captured FX rate is available, money and EPS are normalized to USD for comparison. This is not a historical FX restatement. Gaps are not estimated.
Financial statements load separately from the research page.
Source: . Window ends at the latest available reporting period.
Revenue
Reported figures
Financial data & calculation notes
Standalone charts use the stated reporting currency. When a chart comparison spans currencies, money and EPS can be normalized to USD using a recent captured FX snapshot; this is for comparison only, not a historical FX restatement. Stock-based compensation is noncash. Free cash flow is operating cash flow less capital spending, which may include capitalized software. Missing metrics are not estimated or assumed to be zero. Banking and insurance ratios require industry-specific interpretation. Latest restatements may differ from figures in older episodes.
Market context
Valuation & price history
Adjusted closing price
Price history loads separately.
Price figures
Earnings-multiple scenario
Illustrative price = your earnings-per-share assumption × your P/E assumption. This is not a price target or a complete valuation model.
Starting assumptions, when available, use provider forward estimates as of 2026-10-06. Negative earnings require a different valuation method. This calculation omits balance-sheet, dilution and execution risks.
THE RESEARCH RECORD
Research history for BDX
Q3 FY20262026-08-08
Becton Dickinson (BDX): The Miss That Wasn’t - And The Beat That Also Wasn’t
Presentation · 2026-08-08 · YouTube
Q1 20262026-05-10
BDX Stock: EPS Beats, Revenue Misses — Q1 2026
Presentation · 2026-05-10 · YouTube